Pain Medicine Doctors in Spokane, WA Accepting Medicare

3 Pain Medicine doctors found. Showing 1 - 3

Jillian Savage, Pain Medicine - Interventional Pain Medicine Medicare: Medicare Enrolled Practice Location: 421 W Riverside Ave Ste 900, Spokane, WA 99201 Phone: 509-863-9789    Fax: 509-255-7793

Dr. Lynda K Williamson, D.O. Pain Medicine - Pain Medicine Medicare: Medicare Enrolled Practice Location: 4511 S Glenrose Rd, Spokane, WA 99223 Phone: 509-456-2406    Fax: 509-456-2407

Scott Ray Pleines, PA Pain Medicine - Interventional Pain Medicine Medicare: Medicare Enrolled Practice Location: 551 E Hawthorne Rd, Spokane, WA 99218 Phone: 509-252-1900    Fax: 509-474-5859

News Archive

Access to emergency contraception can help reduce unintended pregnancy in teens

About 22 percent of women between the ages of 15 and 44 report having used emergency contraception. But even though the Food and Drug Administration approved levonorgestrel-more commonly known as Plan B-for over-the-counter use for women of all ages in 2013, it's not always easy to get-especially at local, mom-and-pop drug stores.

Study may explain how chemoresistance evolves over time in some triple-negative breast cancers

Triple-negative breast cancer is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many patients become resistant to treatment.

Children with neuromuscular diseases at risk for decreased bone density

Children with neuromuscular diseases such as muscular dystrophy, may be at risk for suboptimal bone density due to low levels of vitamin D.

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

Moores Cancer Center files IND application for topical NexACT-based formulation

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).

Read more Medical News

› Verified 6 days ago